Rammohan等人,“一个比较的帖子natalizumab停止疾病活动从24个月前基线疾病活动是不可接受的度量论反弹复发。”However, "baseline disease activity from 24 months earlier " was not the metric we chose for relapse comparisons as can be seen in Figures 2 [1] (relapse rates in all patients and in AFFIRM patients)and 3 (relapse rates in those on alternative treatments and highly active cases). [1] In this relapse data, 'baseline' is the on-study placebo rate, not the pre-study placebo rate as Rammohan et al. contend.
我们“反弹”定义为“恶化的疾病活动超越预处理的水平。”By this definition, rebound was not seen in this assessment of by far the largest group of natalizumab-treated patients in the literature. We used this defintion because it seemed reasonable but other definitions could be considered.
Rammohan等人,“一个比较的帖子natalizumab停止疾病活动从24个月前基线疾病活动是不可接受的度量论反弹复发。”However, "baseline disease activity from 24 months earlier " was not the metric we chose for relapse comparisons as can be seen in Figures 2 [1] (relapse rates in all patients and in AFFIRM patients)and 3 (relapse rates in those on alternative treatments and highly active cases). [1] In this relapse data, 'baseline' is the on-study placebo rate, not the pre-study placebo rate as Rammohan et al. contend.
钆增强病变有关,[1]的图4显示的是两个“pre -研究”以及最后的研究数据natalizumab治疗患者与数据点大于6个月治疗后停止。post-cessation大于6个月,很明显,natalizumab治疗的病人的数量提高病变(1.2)高于在研究结束时(0.3)但不是高达预研(1.6)。
我们“反弹”定义为“恶化的疾病活动超越预处理的水平。”By this definition, rebound was not seen in this assessment of by far the largest group of natalizumab-treated patients in the literature. We used this defintion because it seemed reasonable but other definitions could be considered.
这些数据来自一大群病人和数据进行描述的均值和标准差。在任何团体,有些病人会离群值,高于或低于平均水平的疾病活动也许可以解释一些规模较小的情况下系列文献中。
很明显,复发和MRI活动返回natalizumab停止时,这使得决定何时和为什么停止药物,如果有的话,把它换成更加复杂。有一个风险保持在停止药物也是一种风险。
作者披露,见原文。